RO7062931
is a new experimental drug being developed by Roche pharma for treating patients
with Chronic Hepatitis B. Hepatitis B is an infectious disease caused by the
hepatitis B virus (HBV) which affects the liver. It can cause both acute and
chronic infections. Many people have no symptoms during the initial infection. The
virus is transmitted through contact with the blood or other body fluids of an
infected person. An estimated 240 million people are chronically infected with
hepatitis B (defined as hepatitis B surface antigen positive for at least 6
months). However, it can be prevented by currently available safe and effective
vaccine.
 |
| New Drug for Treatment of Chronic Hepatitis B Virus |
RO7062931
is administered subcutaneously and at present it is in Phase I clinical trials
[1, 2].
References:
1. Towards
HBV Cure? Paris Hepatology Conference, 30-31st Jan 2017. (free article)
2. ClinicalTrials.gov A Study to Evaluate
the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of
RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B Recruiting. NCT03038113
